Chevron Corporation (CVX) Hit a 52 Week High, Can the Run Continue?

Chevron shares rose 14% over the past month to a 52-week high of $236.48 and are up 54.5% year to date. The company reported last-quarter EPS of $5.28 versus a $4.78 consensus and has beaten estimates in each of the past four quarters; Zacks assigns it a #1 (Strong Buy) rank. The article also notes a valuation premium at 13x current-fiscal-year EPS estimates versus a 7.5x peer average, while next-fiscal-year EPS and revenue are forecast to decline 4.67% and 0.62%, respectively.

Analysis

The key risk is not that Chevron’s recent operating momentum is fictitious; it is that the equity may be pricing that momentum as more durable than the forward profile supports. The cited next-year EPS decline against roughly flat revenue makes estimate revisions—not the latest beat—the near-term swing factor. If analysts begin rolling down forward earnings, the premium to peers can contract twice: through lower earnings and a lower multiple. The reported 14x cash-flow multiple versus a much lower peer figure also leaves less valuation cushion, though the gap may partly reflect differences in asset mix, balance-sheet quality, and capital-return expectations. The article does not establish that the estimates or peer comparisons are independently verified.

Over days, a new high and strong trailing performance can attract trend-following flows, but they are not evidence of incremental fundamental upside; the weak momentum score is a caution against treating the move as self-validating. Over 1–3 months, watch estimate revisions, realized oil prices, and management’s production/capital-return outlook. Over 6–18 months, commodity normalization would expose the earnings base effect, while sustained supply discipline or stronger-than-expected oil would support the premium. Petrobras (PBR.A) is not a clean valuation substitute: its discount may embed distinct country, currency, and state-intervention risks. The contrarian point is therefore not that Chevron is simply expensive, but that a quality premium may be justified—yet still vulnerable if revisions turn down.

Key Decisions for Investors

• Do not chase CVX solely on the breakout or the reported earnings-surprise streak. For existing exposure, consider a modest underweight versus the energy allocation until forward EPS revisions confirm the rally; avoid an outright short absent a catalyst.
• Set a 1–3 month alert for downward revisions to next-year EPS or weaker production/capital-return guidance. A sustained reversal in those measures would strengthen the case for reducing CVX; stable or rising estimates alongside supportive oil prices would falsify the fade thesis.
• Keep PBR.A as a separate, higher-idiosyncratic-risk value exposure rather than using its headline valuation as a direct short-term hedge for CVX. Verify currency, government policy, and dividend/capital-allocation assumptions before sizing any relative-value position.
• No options trade is justified from the supplied information: option-implied volatility, expiries, and current prices are missing. Reassess only if those data show a reasonably priced way to express downside around an earnings or guidance catalyst.